A comparison of UK and US guidelines for drug treatment in borderline personality disorder

International Review of Psychiatry

Volumn 23, Issue 4, 2011, Pages 388-394

  Tyrer, Peter ^a   Silk, Kenneth R ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; FLUOXETINE; HALOPERIDOL; LITHIUM; MIANSERIN; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PHENELZINE; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; TRANYLCYPROMINE; TRIFLUOPERAZINE; VALPROIC ACID;

BEHAVIOR THERAPY; BORDERLINE STATE; COGNITIVE THERAPY; DRUG INDUSTRY; IMPULSIVENESS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; RISK BENEFIT ANALYSIS; TRANSFERENCE; UNITED KINGDOM; UNITED STATES;

ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; BORDERLINE PERSONALITY DISORDER; GREAT BRITAIN; HUMANS; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 80054881613     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.3109/09540261.2011.606540     Document Type: Review

References (40)

1. Abraham, P.F. & Calabrese, J.R. (2008). Evidenced-based pharmacologic treatment of borderline personality disorder: A shift from SSRIs to anticonvulsants and atypical antipsychotics? Journal of Affective Disorders, 111, 21-30.
2. Adil, J. (2010). Antipsychotics and borderline personality disorder. British Journal of Psychiatry, 196, 332.
3. Adityanjee, Romine, A., Brown, E., Thuras, P., Lee, S. & Schulz, S.C. (2008). Quetiapine in patients with borderline personality disorder: An open-label trial. Annals of Clinical Psychiatry, 20, 219-226.
4. APA (2001). Practice guideline for the treatment of patients with borderline personality disorder. American Journal of Psychiatry, 158S10, 1-52.
5. Bateman, A.W. & Fonagy, P. (1999). The effectiveness of partial hospitalization in the treatment of borderline personality disorder-a randomized controlled trial. American Journal of Psychiatry, 156, 1563-1569.
6. Bateman, A.W. & Fonagy, P. (2008). 8-year follow-up of patients treated for borderline personality disorder: Mentalization-based treatment versus treatment as usual. American Journal of Psychiatry, 165, 631-638.
7. Blum, N., St John, D., Pfohl, B., Stuart, S., McCormick, B., Allen, J., ... Black, D.W. (2008). Systems Training for Emotional Predictability and Problem Solving (STEPPS) for outpatients with borderline personality disorder: A randomized controlled trial and 1-year follow-up. American Journal of Psychiatry, 165, 468-478. (Pubitemid 351694290)
8. Chanen, A.M., Jackson, H.J., McCutcheon, L.K., Jovev, M., Dudgeon, P., Yuen, H.P., ... McGorry, P.D. (2008). Early intervention for adolescents with borderline personality disorder using cognitive analytic therapy: Randomised controlled trial. British Journal of Psychiatry, 1 93, 477-484.
9. Clarkin, J.F., Levy, K.N., Lenzenweger, M.F. & Kernberg, O.F. (2007). Evaluating three treatments for borderline personality disorder: A multiwave study. American Journal of Psychiatry, 164, 922-928. (Pubitemid 46972908)
10. Cowdry, R.W. & Gardner, D.L. (1988). Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Archives of General Psychiatry, 45, 111-119. (Pubitemid 18052841)
11. Davidson, K., Norrie, J., Tyrer, P., Gumley, A., Tata, P., Murray, H. & Palmer, S. (2006). The effectiveness of cognitive behavior therapy for borderline personality disorder: Results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial . Journal of Personality Disorders, 20, 450-465. (Pubitemid 44580879)
12. Davidson, K.M., Tyrer, P., Norrie, J., Palmer. S.J. & Tyrer, H. (2010). Cognitive therapy v. usual treatment for borderline personality disorder: Prospective 6-year follow-up. British Journal of Psychiatry, 197, 456-462.
13. de la Fuente, J.M. & Lotstra, F. (1994). A trial of carbamazepine in borderline personality disorder. European Neuropsychopharmacology, 4, 479-486.
14. Eli Lilly (2007). Efficacy and safety of olanzapine in patients with borderline personality disorder: A randomized double-blind comparison with placebo. (Summary 6253, Clinical Study Summary: Study F1D-MC-HGKK). Available at: http://www.clinicalstudyresults.org.documents/company-study-2339-0.pdf (accessed 22 June 2011).
15. Gaebel, W., Weinmann, S., Sartorius, N., Rutz, W. & McIntyre, J.S. (2005). Schizophrenia practice guidelines: International survey and comparison. British Journal of Psychiatry, 187, 248-255. (Pubitemid 41306106)
16. Giesen-Bloo, J., van Dyck, R., Spinhoven,P., van Tilburg, W., Dirksen, C., van Asselt, T., ... Arntz, A. (2006). Outpatient psychotherapy for borderline personality disorder: Randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry, 63, 649-658. (Pubitemid 43848296)
17. Goldberg, S.C., Schulz, S.C., Schulz, P.M., Resnick, R.J., Hamer, R.M. & Friedel, R.O. (1986). Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Archives of General Psychiatry, 43, 680-686. (Pubitemid 16094180)
18. Guyatt, G.H., Oxman, A.D., Vist, G.E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., ... GRADE Working Group (2008). GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. British Medical Journal, 336, 924-926. (Pubitemid 351632017)
19. Kendall, T., Burbeck, R. & Bateman, A. (2010). Pharmacotherapy for borderline personality disorder: NICE guideline. British Journal of Psychiatry, 196, 158-159.
20. Lieb, K., V ö llm, B., R ü cker, G., Timmer, A. & Stoffers, J.M. (2010). Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. British Journal of Psychiatry, 196, 4-12.
21. Linehan, M.M., Armstrong, H.E., Suarez, A., Allmon, D. & Heard, H.L. (1991). Cognitive behavioural treatment for chronically parasuicidal borderline patients. Archives of General Psychiatry, 48, 1060-1064.
22. Montgomery, S.A. & Montgomery, D. (1982) Pharmacological prevention of suicidal behavior. Journal of Affective Disorders, 4, 291-298.
23. Mulder, R. (2009). Is borderline personality really a personality disorder? Personality and Mental Health, 3, 85.
24. NCCMH (2009). Borderline Personality Disorder: Treatment and management. Leicester & London: British Psychological Society & Royal College of Psychiatrists.
25. Newton-Howes, G. & Tyrer, P. (2003). Pharmacotherapy for personality disorders. Expert Opinion in Pharmacotherapy, 4, 1643-1649.
26. NICE (2009) Borderline Personality Disorder: Treatment and Management. NICE clinical guideline 78. London: NICE. Available from www.nice.org.uk/CG78 (accessed 3 March 2011).
27. Paris, J., Silk, K.R., Gunderson, J., Links, P.S. & Zanarini, M. (2009). The case for retaining borderline personality disorder as a psychiatric diagnosis. Personality and Mental Health, 3, 96-100 .
28. Paton, C. (2008). Prescribing in pregnancy. British Journal of Psychiatry, 192, 321-322.
29. Pope, A., Adams, A., Paton, C., Weaver, T. & Barnes, T.R.E. (2010). Assessment of adverse effects in clinical studies of antipsychotic medication: Survey of methods. British Journal of Psychiatry, 197, 67-72.
30. Rinne, T., van den Brink, W., Wouters, L. & van Dyck, R. (2002). SSRI treatment of borderline personality disorder: A randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. American Journal of Psychiatry, 159, 2048-2054. (Pubitemid 35423864)
31. Salzman, C., Wolfson, A.N., Schatzberg, A., Looper, J., Henke, R., Albanese, M., ... Miyawaki, E. (1995). Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. Journal of Clinical Psychopharmacology, 15, 23-29.
32. Sanislow, C.A., Little, T.D., Ansell, E.B., Grilo, C.M., Daversa, M., Markowitz, J.C., ... McGlashan, T.H. (2009). Ten-year stability and latent structure of the DSM-IV schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders. Journal of Abnormal Psychology, 118, 507-519.
33. Saunders, E.F.H. & Silk, K.R. (2009). Personality trait dimensions and the pharmacologic treatment of borderline personality disorder . Journal of Clinical Psychopharmacology, 29, 461-467.
34. Schulz, S.C., Zanarini, M.C., Bateman, A., Bohus, M., Detke, H.C., Trzaskoma, Q., ... Corya, S. (2008). Olanzapine for the treatment of borderline personality disorder: Variable dose 12-week randomised double-blind placebo-controlled study. British Journal of Psychiatry, 193, 485-492.
35. Siever, L.J. & Davis, K.L. (1991). A psychobiological perspective on the personality disorders. American Journal of Psychiatry, 148, 1647-1658.
36. Soloff, P.H. (1998). Algorithms for pharmacological treatment of personality dimensions: Symptom-specific treatments for cognitiveperceptual, affective, and impulsive-behavioral dysregulation. Bulletin of the Menninger Clinic, 62, 195-214.
37. Soloff, P.H., Cornelius, J., George, A., Nathan, S., Perel, J.M. & Ulrich, R.F. (1993). Efficacy of phenelzine and haloperidol in borderline personality disorder. Archives of General Psychiatry, 50, 377-385. (Pubitemid 23143127)
38. Soloff, P.H., George, A., Nathan, R.S., Schulz, P.M., Cornelius, J.R., Herring, J. & Perel, J.M. (1989). Amitriptyline versus haloperidol in borderlines: Final outcomes and predictors of response. Journal of Clinical Psychopharmacology, 9, 238-246. (Pubitemid 19198957)
39. Tyrer, P. (2009). Why borderline personality disorder is neither borderline nor a personality disorder. Personality and Mental Health, 3, 86-95.
40. Yang, M., Coid, J. & Tyrer, P. (2010). Personality pathology recorded by severity: National survey. British Journal of Psychiatry, 197, 193-199.